Childhood neuroblastoma is often a fatal disease. A new approach using a combination of two drugs shows promise in reducing ...

Topoisomerase 2β (TOP2B) introduces transient double strand breaks in the DNA helix to remove supercoiling structures and unwind entangled DNA strains. Advances in genomic technologies have enabled ...

The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.

Adcendo, a biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical ...

In a study published in Nature, researchers report the successful in vitro reconstitution of meiotic DNA double-strand breaks ...

Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic ...

Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal growth factor receptor 2 (HER2) biparatopic antibody-drug conjugate (ADC), ...

"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...

在肿瘤研究的浩瀚征程中，科学家们从未停止探索的脚步。肿瘤的特征之一是不受控制的细胞分裂，并在此过程中伴随着DNA复制、细胞周期蛋白的表达和激活、微管蛋白重组等细胞活动。一些小分子抑制剂，例如DNA烷化和交联剂、CDK抑制剂等可以高效地阻断上述过程，进 ...